⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLDX News
Celldex Therapeutics, Inc
Cleveland Diagnostics Names Jack Kenny as Chairman of the Board
businesswire.com
CLDX
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
globenewswire.com
CLDX
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
CLDX
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
globenewswire.com
CLDX
Celldex to Present at Upcoming Investor Conferences
globenewswire.com
CLDX
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
globenewswire.com
CLDX
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
globenewswire.com
CLDX
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
globenewswire.com
CLDX